Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,868 18 apr 2024 17:35
  • -0,093 (-9,63%) Dagrange 0,861 - 0,957
  • 37.599.271 Gem. (3M) 6,4M

Plasma

12 Posts
| Omlaag ↓
  1. [verwijderd] 17 juni 2016 10:16
    Omdat schijnbaar de risicos van (bijvoorbeeld) het ZIKA virus blijken mee te vallen volgens de experts hier... toch nog maar een belangrijke draag openen inzake Plasma.

    -------------------------------------------------------------------------------

    National Health Action Party press release 25th May 2016

    The National Health Action Party issued warnings in 2013 about the potentially dangerous consequences of selling the NHS' state owned blood plasma supplier, Plasma Resources UK (PRUK) to US private equity firm Bain Capital. Now we are issuing a warning again as it has been sold on.

    PRUK was specifically brought into public ownership in 1975, by Dr David Owen, because of the risks associated with contaminated blood under for-profit conditions.

    Bain Capital bought an 80% share for £230 million in 2013. Now, just 3 years later, Bain has sold it to Chinese company Creat for 'a total cash consideration of £820m'. China's plasma product supply companies are highly profitable businesses as China is suffering a shortage of these products.

    Creat's press release said 'Creat, a leading Chinese investment group, will invest £100 million in BPL to expand production capacity of lifesaving therapies, develop new products and access new markets. BPL’s existing management team is staying with the company, which will remain headquartered in the UK. Creat will support management’s ambition to transform BPL into a global life-sciences champion, serving more customers and patients in a greater number of markets around the world. Creat is a long-term strategic investor with a track record of growing businesses and a deep knowledge of the plasma sector.

    Currently, BPL is 80% owned by Bain Capital Private Equity and 20% by the UK Department of Health. BPL’s Board of Directors is unanimously supportive of the proposed sale of the company to Creat.'

    Dr Clive Peedell said " Every sale of this kind increases the dangers the public are exposed to by privatisation. Health care is very big business globally. But the NHS should not simply be a market competitor, looking for ways to maximise profit. It should be first and foremost a system which ensures that we all look after each other at our time of greatest need.

    It is extremely worrying to see the NHS' blood plasma supplies being written about only in the context of accessing more markets around the world, with no mention of the NHS, only to the Department of Health being a 20% shareholder.

    I am increasingly worried by George Osborne's economic strategy. His only serious policy seems to be to sell off everything the state owns as a short term fix for balancing the books, whilst the public suffers the loss of services.

    The loss of blood plasma supplies will have dreadful consequences for patients, as will the potential increased risk of contamination. And I am warning that these are the real risks when lucrative global markets are the prime objective, not our own patient care in the NHS."
  2. [verwijderd] 17 juni 2016 11:48
    quote:

    RRR schreef op 17 juni 2016 10:16:

    Omdat schijnbaar de risicos van (bijvoorbeeld) het ZIKA virus blijken mee te vallen volgens de experts hier... toch nog maar een belangrijke draag openen inzake Plasma.

    -------------------------------------------------------------------------------

    National Health Action Party press release 25th May 2016

    The National Health Action Party issued warnings in 2013 about the potentially dangerous consequences of selling the NHS' state owned blood plasma supplier, Plasma Resources UK (PRUK) to US private equity firm Bain Capital. Now we are issuing a warning again as it has been sold on.

    PRUK was specifically brought into public ownership in 1975, by Dr David Owen, because of the risks associated with contaminated blood under for-profit conditions.

    Bain Capital bought an 80% share for £230 million in 2013. Now, just 3 years later, Bain has sold it to Chinese company Creat for 'a total cash consideration of £820m'. China's plasma product supply companies are highly profitable businesses as China is suffering a shortage of these products.

    Creat's press release said 'Creat, a leading Chinese investment group, will invest £100 million in BPL to expand production capacity of lifesaving therapies, develop new products and access new markets. BPL’s existing management team is staying with the company, which will remain headquartered in the UK. Creat will support management’s ambition to transform BPL into a global life-sciences champion, serving more customers and patients in a greater number of markets around the world. Creat is a long-term strategic investor with a track record of growing businesses and a deep knowledge of the plasma sector.

    Currently, BPL is 80% owned by Bain Capital Private Equity and 20% by the UK Department of Health. BPL’s Board of Directors is unanimously supportive of the proposed sale of the company to Creat.'

    Dr Clive Peedell said " Every sale of this kind increases the dangers the public are exposed to by privatisation. Health care is very big business globally. But the NHS should not simply be a market competitor, looking for ways to maximise profit. It should be first and foremost a system which ensures that we all look after each other at our time of greatest need.

    It is extremely worrying to see the NHS' blood plasma supplies being written about only in the context of accessing more markets around the world, with no mention of the NHS, only to the Department of Health being a 20% shareholder.

    I am increasingly worried by George Osborne's economic strategy. His only serious policy seems to be to sell off everything the state owns as a short term fix for balancing the books, whilst the public suffers the loss of services.

    The loss of blood plasma supplies will have dreadful consequences for patients, as will the potential increased risk of contamination. And I am warning that these are the real risks when lucrative global markets are the prime objective, not our own patient care in the NHS."
  3. [verwijderd] 17 juni 2016 14:52
    quote:

    $rob$ schreef op 17 juni 2016 13:05:

    [...]
    Ik vind jou wel de grootste expert hier Triple.....
    Jij zegt altijd precies te weten wanneer de koers omhoog gaat, wanneer er een PB komt, wanneer er ander nieuws aankomt.....dat maakt jou een expert.
    Een gemaakte expert? Neenee, dat is teveel eer...dat laat ik aan andeen over.
  4. [verwijderd] 17 juni 2016 15:22
    Studies on the Safety and Efficacy of Plasma-derived Products and Their Recombinant Analogs
    Principal Investigator: Basil Golding, MD
    Office / Division / Lab: OBRR / DH / LPD

    General Overview
    The goal of our research is to enhance the safety of plasma-derived products, such as proteins used to treat clotting disorders, immune system disorders, and certain other diseases.

    Our laboratory is pursuing this goal by developing tests that detect contamination of these products by substances released by microorganisms. Although microbes are filtered out of plasma used to make the products, the small molecules they make can escape filtration and trigger inflammation in individuals treated with the products.

    Our tests use a variety of cells that carry molecules called toll-like receptors (TLRs) on their surface. Each group of cells carries a specific type of TLR, which detects and binds to a specific protein made by microorganisms. Tests based on this interaction between TLRs and these proteins, called TLR ligands, will help FDA and industry screen plasma-derived products for contamination by microorganisms or their products.

    FDA will make any tests that we develop available to industry so they can be used to increase the safety of plasma-derived products.

    Lekker spulletje... die plasma zooi...

    Zeg maar gerust linke zooi!

    bron: www.fda.gov/BiologicsBloodVaccines/Sc...
12 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Logische herfinanciering Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links